Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588406 · ClinicalTrials.gov registry record · Phase 3
Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.
A Phase 3 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
NCT00588406 is a Phase 3 study that has completed, run by Northwell Health. The registered enrollment target is 95 participants.
The verdict
NCT00588406, a Phase 3 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
Study Summary
To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.
Interventions
- DRUG Prednisone
- DRUG Budesonide
- DRUG albuterol
- DRUG Ipratropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588406
The ClinicalTrials.gov registry entry for NCT00588406 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT00588406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00588406 about?
NCT00588406 is a clinical study titled "Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.". To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.
What is the current status of trial NCT00588406?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2007-09. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00588406?
The interventions under investigation include: Prednisone (DRUG), Budesonide (DRUG), albuterol (DRUG), Ipratropium bromide (DRUG).
Who is sponsoring clinical trial NCT00588406?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.